Therapeutic strategies in Huntington’s disease

Bibliography

• HARPER PS: Huntington's disease. Harper WS (Ed.), WB Saunders, Philadelphia, USA (1996).
   Google Scholar
• THE HUNTINGTON'S DISEASE COLLABORATIVE RESEARCH GROUP: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell (1993) 72:971–983.
   Google Scholar
• MACDONALD ME, GUSELLA JF: Huntington's disease: translating a CAG repeat into a pathogenic mechanism. Carr: Opin. Neurobiol (1996) 6:638–643.
   PubMedGoogle Scholar
• MARGOLIS RL, ROSS CA: Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases. Trends Ma Med. (2001) 7:479–482.
   PubMedGoogle Scholar
• MCMURRAY CT: Huntington's disease: new hope for therapeutics. Trends Neurosci.(2001) 24:32–38.
   PubMedGoogle Scholar
• REINER A, ALBIN RL, ANDERSON KD, D'AMATO CJ, PENNEY JB, YOUNG AB: Differential loss of striatal projection neurons in Huntington's disease. Proc. Nati Acad. Sci. USA (1988) 85:5733–5737.
   PubMed Web of Science ®Google Scholar
• RICHFIELD EK, MAGUIRE-ZEISS KA, VONKEMAN HE, VOORN P: Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann. Neurol (1995) 38:852–861.
   PubMedGoogle Scholar
• CICCHETTI F, PRENSA L, WU Y, PARENT A: Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res. Rev (2000) 34:80–101.
   PubMedGoogle Scholar
• DAWBARN D, DE QUIDT ME, EMS ON PC: Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res. (1985) 340:251–260.
   PubMed Web of Science ®Google Scholar
• FERRANTE RJ, KOWALL NW, BEAL ME RICHARDSON EPJ, BIRD ED, MARTIN JB: Selective sparing of a class of striatal neurons in Huntington's disease. Science (1985) 230:561–563.
   PubMed Web of Science ®Google Scholar
• CUDKOWICZ M, KOWALL NW: Degeneration of pyramidal projection neurons in Huntington's disease cortex. Ann. Neurol (1990) 27:200–204.
   PubMed Web of Science ®Google Scholar
• DIFIGLIA M, SAPP E, CHASE KO et al:Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 277:1990–1993.
   PubMed Web of Science ®Google Scholar
• MACDONALD V, HALLIDAY G: Pyramidal cell loss in motor cortices in Huntington's disease. Neurobiol Dis. (2002) 10:378–386.
   PubMedGoogle Scholar
• BARTENSTEIN P, WEINDL A, SPIEGEL S et al.: Central motor processing in Huntington's disease. A PET study. Brain (1997) 120(Pt 9):1553–1567.
   Google Scholar
• ROSAS HD, LIU AK, HERSCH S et al: Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology(200 2) 58:695–701.
   Google Scholar
• SAX DS, POWSNER R, KIM A et al.: Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photon-emission computed tomography. Mov. Disord. (1996) 11:671–677.
   PubMedGoogle Scholar
• WEEKS RA, CEBALLOS-BAUMANN A, PICCINI P, BOECKER H, HARDING AE, BROOKS DJ: Cortical control of movement in Huntington's disease. A PET activation study. Brain (1997) 120(Pt 9):1569–1578.
   Google Scholar
• LAFORET GA, SAPP E, CHASE K et al:Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. Neurosci. (2001) 21:9112–9123.
   Google Scholar
• DUYAO MP, AUERBACH AB, RYAN A et al.: Inactivation of the mouse Huntington's disease gene homolog Hdh. Science (1995) 269:407–410.
   PubMed Web of Science ®Google Scholar
• NASIRJ, FLORESCO SB, O'KUSKY JR et al.: Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell (1995) 81:811–823.
   Google Scholar
• GUSELLA JF, MACDONALD ME: Huntingtin: a single bait hooks many species. Carr. Opin. Neurobiol (1998) 8:425–430.
   PubMedGoogle Scholar
• CATTANEO E, RIGAMONTI D, GOFFREDO D, ZUCCATO C, SQUITIERI F, SIPIONE S: Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. (2001) 24:182–188.
   PubMed Web of Science ®Google Scholar
• •Interesting review discussing the possible mechanisms of action of mutated Huntingtin.
   Google Scholar
• BHIDE PG, DAY M, SAPP E et al: Expression of normal and mutant huntingtin in the developing brain. J. Neurosci. (1996) 16:5523–5535.
   PubMed Web of Science ®Google Scholar
• LANDWEHRMEYER GB, MCNEIL SM, DURE LS et al.: Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. Ann. Neurol (1995) 37:218–230.
   PubMedGoogle Scholar
• SHARP AH, LOEV SJ, SCHILLING G et al.: Widespread expression of Huntington's disease gene (IT15) protein product. Neuron (1995) 14:1065–1074.
   PubMedGoogle Scholar
• FERRANTE RJ, GUTEKUNST CA, PERSICHETTI F et al.: Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. Neurosci. (1997) 17:3052–3063.
   Google Scholar
• KOSINSKI CM, CHA JH, YOUNG AB et al.: Huntingtin immunoreactivity in the rat neostriatum: differential accumulation in projection and interneurons. Exp. Neurol (1997) 144:239–247.
   PubMedGoogle Scholar
• FUSCO FR, CHEN Q, LAMOREAUX WJ et al.: Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. Neurosci. (1999) 19:1189–1202.
   Google Scholar
• •This study shows that Huntingtin is not consistently expressed by striatal projection neurons (the most affected in HD), while it is abundant in striatal large interneurons (that are spared in HD) and suggest that mechanisms other than mutated Huntingtin may be involved in striatal neuron degeneration.
   Google Scholar
• DAVIES SW, TURMAINE M, COZENS BA et al: Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell (1997) 90:537–548.
   PubMed Web of Science ®Google Scholar
• MAAT-SCHIEMAN ML, DORSMAN JC, SMOOR MA et al: Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington's disease brain. Neuropathol Exp. Neurol (1999) 58:129–137.
   PubMedGoogle Scholar
• SAUDOU F, FINKBEINER S, DEVYS D, GREENBERG ME: Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell (1998) 95:55–66.
   PubMed Web of Science ®Google Scholar
• KIM M, LEE HS, LAFORET G et al.: Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. Neurosci. (1999) 19:964–973.
   Google Scholar
• MARTINDALE D, HACKAM A, WIECZOREK A et al.: Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet. (1998) 18:150–154.
   PubMed Web of Science ®Google Scholar
• DEDEOGLU A, KUBILUS JK, JEITNER TM et al.: Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. (2002) 22:8942–8950.
   PubMed Web of Science ®Google Scholar
• KARPUJ MV, BECHER MW, SPRINGER JE et al: Prolonged survival and decreased abnormal movements in transgenic model of Huntington's disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. (2002) 8:143–149.
   PubMed Web of Science ®Google Scholar
• CHA JH: Transcriptional dysregulation in Huntington's disease. Trends Neurosci. (2000) 23:387–392.
   PubMed Web of Science ®Google Scholar
• SIPIONE S, RIGAMONTI D, VALENZA M et al.: Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Ma Genet. (2002) 11:1953–1965.
   PubMed Web of Science ®Google Scholar
• STEFFAN JS, BODAI L, PALLOS J et al.:Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature (2001) 413:739–743.
   PubMed Web of Science ®Google Scholar
• HOCKLY E, RICHON VM, WOODMAN B et al.: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci.USA (2003) 100:2041–2046.
   PubMed Web of Science ®Google Scholar
• PORTERA-CAILLIAU C, HEDREEN JC,PRICE DL, KOLIATSOS VE: Evidence for apoptotic cell death in Huntington's disease and excitotoxic animal models. J. Neurosci. (1995) 15:3775–3787.
   PubMed Web of Science ®Google Scholar
• RIGAMONTI D, BAUER JH, DE-FRAJA C et al.: Wild-type huntingtin protects from apoptosis upstream of caspase-3. Neurosci. (2000) 20:3705–3713.
   Google Scholar
• GERVAIS FG, SINGARAJA R, XANTHOUDAKIS S et al.: Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat. Cell Biol. (2002) 4:95–105.
   PubMedGoogle Scholar
• ONA VO, LI M, VONSATTEL JP et at Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature (1999) 399:263–267.
   PubMed Web of Science ®Google Scholar
• CHEN M, ONA VO, LI M et al: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease. Nat. Med. (2000) 6:797–801.
   PubMed Web of Science ®Google Scholar
• CALABRESI P, PISANI A, MERCURI NB, BERNARDI G: The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. (1996) 19:19–24.
   PubMedGoogle Scholar
• STERN EA, JAEGER D, WILSON CJ: Membrane potential synchrony of simultaneously recorded striatal spiny neurons in vivo. Nature (1998) 394:475–478.
   PubMedGoogle Scholar
• PISANI A, CALABRESI P, CENTONZE D, MARFIA GA, BERNARDI G: Electrophysiological recordings and calcium measurements in striatal large aspiny interneurons in response to combined 02/glucose deprivation. J. Neurophysiol (1999) 81:2508–2516.
   PubMedGoogle Scholar
• BENNETT BD, WILSON CJ: Spontaneous activity of neostriatal cholinergic interneurons in vitro. J. Neurosci. (1999) 19:5586–5596.
   PubMed Web of Science ®Google Scholar
• BEAL ME KOWALL NW, ELLISON DW, MAZUREK ME SWARTZ KJ, MARTIN JB: Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature (1986) 321:168–171.
   PubMedGoogle Scholar
• •First study showing the selective striatal neuronal degeneration, with loss of projection neurons and sparing of striatal interneurons, induced by treatment with the NMDA receptor agonist, quinolinic acid.
   Google Scholar
• BROUILLET E, CONDE F, BEAL ME HANTRAYE P: Replicating Huntington's disease phenotype in experimental animals. Frog. Neurobiol (1999) 59:427–468.
   Google Scholar
• ALBERCH J, PEREZ-NAVARRO E, CANALS JM: Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res. Bull. (2002) 57:817–822.
   PubMedGoogle Scholar
• ALEXI T, BORLONGAN CV, FAULL RL et al.: Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Frog. Neurobiol (2000) 60:409–470.
   Google Scholar
• ••Excellent review addressing the differentmechanisms of neuronal cell death involved in neurodegenerative disorders of the basal ganglia and providing data on the possible neuroprotective strategies.
   Google Scholar
• SOFRONIEW MV, HOWE CL, MOBLEY WC: Nerve growth factor signaling, neuroprotection, and neural repair. Ann. Rev Neurosci. (2001) 24:1217–1281.
   PubMed Web of Science ®Google Scholar
• CHOI DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron (1988) 1:623–634.
   PubMed Web of Science ®Google Scholar
• HOLLMANN M, HEINEMANN S: Cloned glutamate receptors. Ann. Rev Neurosci. (1994) 17:31–108.
   PubMed Web of Science ®Google Scholar
• BERNARD V, SOMOGYI P, BOLAM JP: Cellular, subcellular, and subsynaptic distribution of AMPA-type glutamate receptor subunits in the neostriatum of the rat. Neurosci. (1997) 17:819–833.
   Google Scholar
• CHEN Q, VEENMAN CL, REINER A: Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity. Neuroscience (1996) 73:715–731.
   PubMedGoogle Scholar
• •Paper describing the expression of ionotropic glutamate receptor subunits by striatal neuronal populations and suggesting that the differential expression of these receptors may account for the selective vulnerability of striatal projection neurons to excitotoxicity.
   Google Scholar
• GOTZ T, KRAUSHAAR U, GEIGER J, LUBKE J, BERGER T, JONAS P: Functional properties of AMPA and NMDA receptors expressed in identified types of basal ganglia neurons. Neurosci. (1997) 17:204–215.
   Google Scholar
• LANDWEHRMEYER GB, STANDAERT DG, TESTA CM, PENNEY JBJ, YOUNG AB: NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. Neurosci. (1995) 15:5297–5307.
   Google Scholar
• STANDAERT DG, TESTA CM, YOUNG AB, PENNEY JBJ: Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. Comp. Neurol (1994) 343:1–16.
   PubMed Web of Science ®Google Scholar
• BULLER AL, LARSON HC, SCHNEIDER BE, BEATON JA, MORRISETT RA, MONAGHAN DT: The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. Neurosci. (1994) 14:5471–5484.
   Google Scholar
• CEPEDA C, ITRI JN, FLORES-HERNANDEZ J, HURST RS, CALVERT CR, LEVINE MS: Differential sensitivity of medium- and large-sized striatal neurons to NMDA but not kainate receptor activation in the rat. Eut: Neurosci. (2001) 14:1577–1589.
   PubMedGoogle Scholar
• CALABRESI P, CENTONZE D, PISANI A et al.: Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann. Neural. (1998) 43:586–597.
   PubMedGoogle Scholar
• CALABRESI p, CENTONZE D, BERNARDI G: Cellular factors controlling neuronal vulnerability in the brain: a lesson from the striatum. Neurology(2000) 55:1249–1255.
   PubMedGoogle Scholar
• GRATACOS E, PEREZ-NAVARRO E, TOLOSA E, ARENAS E, ALBERCH J: Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members. I Neurochem. (2001) 78:1287–1296.
   PubMed Web of Science ®Google Scholar
• DAVIES SW, ROBERTS PJ: Sparing of cholinergic neurons following quinolinic acid lesions of the rat striatum. Neuroscience (1988) 26:387–393.
   PubMedGoogle Scholar
• ZERON MM, HANSSON 0, CHEN N et al.: Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron (2002) 33:849–860.
   Google Scholar
• ••Interesting paper showing the involvementof the NR2B subunit of the NMDA receptor in the pathogenesis of HD.
   Google Scholar
• CHEN N, LUO T, WELLINGTON C et al.: Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. Neurochem. (1999) 72:1890–1898.
   PubMed Web of Science ®Google Scholar
• ZERON MM, CHEN N, MOSHAVER A et al.: Mutant huntingtin enhances excitotoxic cell death. MM. Cell Neurosci. (2001) 17:41–53.
   PubMedGoogle Scholar
• NAKANISHI S: Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity. Neuron (1994) 13:1031–1037.
   PubMed Web of Science ®Google Scholar
• BRUNO V, BATTAGLIA G, COPANI A et al.: Metabotropic glutamate receptors and neurodegeneration. Frog. Brain Res. (1998) 116:209–221.
   PubMedGoogle Scholar
• TESTA CM, FRIBERG IK, WEISS SW, STANDAERT DG: Immunohistochemical localization of metabotropic glutamate receptors mGluRla and mGluR2/3 in the rat basal ganglia.' Comp. Near& (1998) 390:5–19.
   PubMedGoogle Scholar
• KERNER JA, STANDAERT DG, PENNEY JBJ, YOUNG AB, LAND WEHRMEYER GB: Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. Ma Brain Res. (1997) 48:259–269.
   Google Scholar
• CALABRESI P, CENTONZE D, PISANI A, BERNARDI G: Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease. Exp. Neurol (1999) 158:97–108.
   PubMed Web of Science ®Google Scholar
• CHA JH, KOSINSKI CM, KERNER JA et al.: Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington's disease gene. Proc. Nati Acad. Sci.USA (1998) 95:6480–6485.
   PubMed Web of Science ®Google Scholar
• ORLANDO LR, ALSDORF SA, PENNEY JBJ, YOUNG AB: The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity. Exp. Neurol (2001) 167:196–204.
   PubMedGoogle Scholar
• BEAL MF: Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. (2000) 23:298–304.
   PubMed Web of Science ®Google Scholar
• HAYDEN MR, MARTIN WR, STOESSL AJ et al.: Positron emission tomography in the early diagnosis of Huntington's disease. Neurology (1986) 36:888–894.
   PubMed Web of Science ®Google Scholar
• KUWERT T, LANGE HW, BOECKER H et al.: Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. J. Neurol (1993) 241:31–36.
   PubMed Web of Science ®Google Scholar
• KOROSHETZ WJ, JENKINS BG, ROSEN BR, BEAL MF: Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol (1997) 41:160–165.
   PubMed Web of Science ®Google Scholar
• LODI R, SCHAPIRA AH, MANNERS D et al.: Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol (2000) 48:72–76.
   PubMed Web of Science ®Google Scholar
• BUTTERWORTH J, YATES CM, REYNOLDS GP: Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and7-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J. Neurol. Sci. (1985) 67:161–171.
   PubMed Web of Science ®Google Scholar
• BROWNE SE, BOWLING AC, MACGARVEY U et al.: Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. (1997) 41:646–653.
   PubMed Web of Science ®Google Scholar
• TABRIZI SJ, CLEETER MW, XUEREB J,TAANMAN JW, COOPER JM, SCHAPIRA AH: Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. (1999) 45:25–32.
   PubMed Web of Science ®Google Scholar
• SAWA A, WIEGAND GW, COOPER J et al.: Increased apoptosis of Huntington's disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. (1999) 5:1194–1198.
   PubMedGoogle Scholar
• PANOV AV, GUTEKUNST CA, LEAVITT BR et al.: Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. (2002) 5:731–736.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-PERNAUTE R, GARCIA-SEGURA JM, DEL BARRIO A, VIANO J, DE YEBENES JG: Clinical correlation of striatal 'H MRS changes in Huntington's disease. Neurology (1999) 53:806–812.
   PubMed Web of Science ®Google Scholar
• BEAL ME BROUILLET E, JENKINS BG et al.: Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. Neurosci. (1993) 13:4181–4192.
   Google Scholar
• BROUILLET E, HANTRAYE P, FERRANTE RJ et al.: Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl Acad. ScL USA (1995) 92:7105–7109.
   PubMed Web of Science ®Google Scholar
• •Study showing that treatment with 3-nitropropionic acid replicates the neuropathological and clinical features of HD in non-human primates and pointing to the involvement of impaired energy metabolism in HD pathogenesis.
   Google Scholar
• GUYOT MC, HANTRAYE P, DOLAN R, PALFI S, MAZIERE M, BROUILLET E: Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience (1997) 79:45–56.
   PubMed Web of Science ®Google Scholar
• PALFI S, FERRANTE RJ, BROUILLET E et al.: Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. NeuroscL (1996) 16:3019–3025.
   PubMedGoogle Scholar
• JENKINS BG, KLIVENYI P, KUSTERMANN E et al: Non-linear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. j Neurochein. (2000) 74:2108–2119.
   PubMed Web of Science ®Google Scholar
• VAN DELLEN A, WELCH J, DIXON RIVI et al: N-acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport (2000) 11:3751–3757.
   PubMedGoogle Scholar
• LINDSAY RM, WIEGAND SJ, ALTAR CA, DISTEFANO PS: Neurotrophic factors: from molecule to man. Trends NeuroscL (1994) 17:182–190.
   PubMed Web of Science ®Google Scholar
• PATAPOUTIAN A, REICHARDT LF: Trk receptors: mediators of neurotrophin action. Carr. Opin. Neurobiol (2001) 11:272–280.
   PubMed Web of Science ®Google Scholar
• CONNOR B, DRAGUNOW M: The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Rev. (1998) 27:1–39.
   PubMed Web of Science ®Google Scholar
• EMERICH DF: Neuroprotective possibilities for Huntington's disease. Expert Opin. Biol. Ther. (2001) 1:467–479.
   PubMed Web of Science ®Google Scholar
• NAKAO N, ODIN P, LINDVALL 0, BRUNDIN P: Differential trophic effects of basic fibroblast growth factor, insulin-like growth factor-1, and neurotrophin-3 on striatal neurons in culture. Exp. Neurol. (1996) 138:144–157.
   PubMedGoogle Scholar
• REYNOLDS BA, TETZLAFF W, WEISS S:A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. Neurosci. (1992) 12:4565-4574. loo. VENTIMIGLIA R, MATHER PE, JONES BE, LINDSAY RM: The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur. NeuroscL (1995) 7:213–222.
   Google Scholar
• WIDMER HR, HEFTI F: Neurotrophin-4/5 promotes survival and differentiation of rat striatal neurons developing in culture. Eur. Neurosci. (1994) 6:1669–1679.
   PubMedGoogle Scholar
• GRATACOS E, CHECA N, ALBERCH J: Bone morphogenetic protein-2, but not bone morphogenetic protein-7, promotes dendritic growth and calbindin phenotype in cultured rat striatal neurons. Neuroscience (2001) 104:783–790.
   PubMedGoogle Scholar
• HATTORI A, KATAYAMA M, IWASAKI S, ISHII K, TSUJIMOTO M, KOHNO M: Bone morphogenetic protein-2 promotes survival and differentiation of striatal GABAergic neurons in the absence of glial cell proliferation. Neurochein. (1999) 72:2264–2271.
   PubMedGoogle Scholar
• HUMPEL C, MARKSTEINERJ, SARIA A: Glial-cell-line-derived neurotrophic factor enhances biosynthesis of substance P in striatal neurons in vitro. Cell Tissue Res. (1996) 286:249–255.
   PubMedGoogle Scholar
• FARKAS LM, SUTER-CRAZZOLARA C, UNSICKER K: GDNF induces the calretinin phenotype in cultures of embryonic striatal neurons. J. NeuroscL Res. (1997) 50:361–372.
   PubMedGoogle Scholar
• CANALS JM, MARCO S, CHECA N et al: Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease. Neurobiol Dis. (1998) 5:357–364.
   PubMedGoogle Scholar
• CANALS JM, CHECA N, MARCO S, MICHELS A, PEREZ-NAVARRO E, ALBERCH J: The neurotrophin receptors trkA, trkB and trkC are differentially regulated after excitotoxic lesion in rat striatum. Ma Brain Res. (1999) 69:242–248.
   Google Scholar
• CHECA N, CANALS JM, GRATACOS E, ALBERCH J: TrkB and TrkC are differentially regulated by excitotoxicity during development of the basal ganglia. Exp. Neurol. (2001) 172:282-292. los. MARCO S, CANUDAS AM, CANALS JM, GAVALDA N, PEREZ-NAVARRO E, ALBERCH J: Excitatory amino acids differentially regulate the expression of GDNF, neurturin, and their receptors in the adult rat striatum. Exp. Neurol. (2002) 174:243–252.
   Google Scholar
• PEREZ-NAVARRO E, ALBERCH J, NEVEU I, ARENAS E: Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo. Neuroscience (1999) 91:1257–1264.
   PubMedGoogle Scholar
• PEREZ-NAVARRO E, CANUDAS AM, AKERUND P, ALBERCH J, ARENAS E: Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. j Neurochein (2000) 75:2190–2199.
   PubMedGoogle Scholar
• PEREZ-NAVARRO E, ARENAS E, REIRIZ J, CALVO N, ALBERCH J: Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage. Neuroscience (1996) 75:345–352.
   PubMedGoogle Scholar
• •First study showing neuroprotective effects of GDNF on striatal projection neurons in the quinolinic acid model of HD.
   Google Scholar
• ARAUJO DM, HILT DC: Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease. Neuroscience (1997) 81:1099–1110.
   PubMedGoogle Scholar
• PEREZ-NAVARRO E, ARENAS E, MARCO S, ALBERCH J: Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo. Eur: Neurosci. (1999) 11:241–249.
   PubMedGoogle Scholar
• MARCO S, PEREZ-NAVARRO E, TOLOSA E, ARENAS E, ALBERCH J: Striatopallidal neurons are selectively protected by neurturin in an excitotoxic model of Huntington's disease. Neurobiol (2002) 50:323–332.
   Google Scholar
• EMERICH DF, WINN SR, HANTRAYE PM et al.: Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature (1997) 386:395–399.
   PubMed Web of Science ®Google Scholar
• EMERICH DF, LINDNER MD, WINN SR, CHEN EY, FRYDEL BR, KORDOWERJH: Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. Neurosci. (1996) 16:5168–5181.
   Google Scholar
• EMERICH DF, CAIN CK, GRECO C et al.: Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. Cell Transplant. (1997) 6:249–266.
   PubMed Web of Science ®Google Scholar
• MITTOUX V, JOSEPH JM, CONDE F et al.: Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum. Gene Ther. (2000) 11:1177–1187.
   PubMed Web of Science ®Google Scholar
• REGULIER E, PEREIRA DA, SOMMER B, AEBISCHER P, DEGLON N: Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Hum. Gene Thec (2002) 13:1981–1990.
   PubMedGoogle Scholar
• MITTOUX V, OUARY S, MONVILLE C et al.: Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration.' Neurosci. (2002) 22:4478–4486.
   PubMedGoogle Scholar
• ALEXI T, VENERO JL, HEFTI F: Protective effects of neurotrophin-4/5 and transforming growth factor-a on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid. Neuroscience (1997) 78:73–86.
   PubMedGoogle Scholar
• FRIM DM, UHLER TA, SHORT MP et al.: Effects of biologically delivered NGF, BDNF and bEGF on striatal excitotoxic lesions. Neuroreport (1993) 4:367–370.
   PubMed Web of Science ®Google Scholar
• KIRSCHNER PB, HENSHAW R, WEISE J et al.: Basic fibroblast growth factor protects against excitotoxicity and chemical hypoxia in both neonatal and adult rats. j Cereb. Blood Flow Metab. (1995) 15:619–623.
   PubMed Web of Science ®Google Scholar
• CANALS JM, CHECA N, MARCO S et al.: Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. j Neurosci. (2001) 21:117–124.
   PubMed Web of Science ®Google Scholar
• •This paper shows that cortical neurons activate an endogenous trophic mechanism after the loss of the striatum in a rat model of HD.
   Google Scholar
• ZUCCATO C, CIAMMOLA A, RIGAMONTI D et al: Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 293:493–498.
   PubMed Web of Science ®Google Scholar
• •Study showing a direct interaction between Huntingtin protein and the neurotrophin BDNE
   Google Scholar
• FERRER I, GOUTAN E, MARIN C, REY MJ, RIBALTA T: Brain-derived neurotrophic factor in Huntington's disease. Binh] Res. (2000) 866:257–261.
   Google Scholar
• SHOULSON I, ODOROFF C, OAKES D et al.: A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann. Nemo] (1989) 25:252–259.
   PubMed Web of Science ®Google Scholar
• KIEBURTZ K: Antiglutamate therapies in Huntington's disease." Neural Transm. Sapp] (1999) 55:97–102.
   PubMedGoogle Scholar
• PALFI S, RICHE D, BROUILLET E et al: Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Exp. Nemo] (1997) 146:135–141.
   PubMed Web of Science ®Google Scholar
• SCHIEFER J, LAND WEHRMEYER GB, LUESSE HG et al.: Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord. (2002) 17:748–757.
   PubMed Web of Science ®Google Scholar
• ROSAS HD, KOROSHETZ WJ, JENKINS BG et al: Riluzole therapy in Huntington's disease (HD). Mov. Disord. (1999) 14:326–330.
   PubMed Web of Science ®Google Scholar
• SEPPI K, MUELLER J, BODNER T et al: Riluzole in Huntington's disease (HD): an open label study with 1 year follow up. Neurol (2001) 248:866–869.
   Google Scholar
• VERHAGEN ML, MORRIS MJ, FARMER C et al: Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology (2002) 59:694–699.
   PubMed Web of Science ®Google Scholar
• SCHILLING G, COONFIELD ML, ROSS CA, BORCHELT DR: Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. (2001) 315:149–153.
   PubMed Web of Science ®Google Scholar
• FERRANTE RJ, ANDREASSEN OA, DEDEOGLU A et al.: Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.' Neurosci. (2002) 22:1592–1599.
   PubMedGoogle Scholar
• THE HUNTINGTON STUDY GROUP: A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology (2001) 57:397–404.
   PubMedGoogle Scholar
• GLASS M, DRAGUNOW M, FAULL RL: The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience (2000) 97:505–519.
   PubMed Web of Science ®Google Scholar
• ONDO WG, TINTNER R, THOMAS M, JANKOVIC J: Tetrabenazine treatment for Huntington's disease-associated chorea. Clin. Neuropharmacol (2002) 25:300–302.
   PubMed Web of Science ®Google Scholar
• JAKEL RJ, MARAGOS WF: Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. (2000) 23:239–245.
   PubMedGoogle Scholar
• GREENAMYRE JT, SHOULSON I: Huntington's Disease, neurodegenerative diseases. Calne DB (Ed.), WB Saunders, Philadelphia, USA (1994).
   Google Scholar
• LASTRES-BECKER I, DE MIGUEL R, DE PETROCELLIS L, MAKRIYANNIS A, DI MARZO V, FERNANDEZ-RUIZ J: Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Neurochem. (2003) 84:1097–1109.
   PubMed Web of Science ®Google Scholar
• BLUM D, GALL D, GALAS MC, D'ALCANTARA P, BANTUBUNGI K, SCHIFFMANN SN: The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.f NeuroscL (2002) 22:9122–9133.
   PubMedGoogle Scholar
• POPOLI P, PINTOR A, DOMENICI MR et al.: Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. Neurosci. (2002) 22:1967–1975.
   Google Scholar
• PEREZ-SEVERIANO F, RIOS C, SEGOVIA J: Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. (2000) 862:234–237.
   PubMed Web of Science ®Google Scholar
• CLIFFORD JJ, DRAGO J, NATOLI AL et al.: Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience (2002) 109:81–88.
   PubMed Web of Science ®Google Scholar
• PURI BK, BYDDER GM, COUNSELL SJ et al.: MRI and neuropsychological improvement in Huntington's disease following ethyl-EPA treatment. Neuroreport (2002) 13:123–126.
   PubMed Web of Science ®Google Scholar
• APFEL SC: Is the therapeutic application of neurotrophic factors dead? Ann. Neurol(2002) 51:8–11.
   Google Scholar
• THOENEN H, SENDTNER M: Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. (2002) 5 (Suppl.):1046–1050.
   Google Scholar
• KORDOWER JH, ISACSON 0, EMERICH DF: Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible? Exp. Neurol (1999) 159:4–20.
   Web of Science ®Google Scholar
• BACHOUD-LEVI AC, DEGLON N, NGUYEN JP et al.: Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTE Hum. Gene Then (2000) 11:1723–1729.
   Google Scholar
• PALFI S, CONDE F, RICHE D et al: Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington's disease. Nat. Med. (1998) 4:963–966.
   PubMed Web of Science ®Google Scholar
• KENDALL AL, HANTRAYE p, PALFI S: Striatal tissue transplantation in non-human primates. Prog. Brain Res. (2000) 127:381–404.
   PubMedGoogle Scholar
• BACHOUD-LEVI AC, REMY P, NGUYEN JP et al: Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet (2000) 356:1975–1979.
   PubMed Web of Science ®Google Scholar
• •Study showing that grafting of human fetal striatal tissue in HD patients partially improves motor and cognitive functions.
   Google Scholar
• HAUSER RA, SANDBERG PR, FREEMAN TB, STOESSL AJ: Bilateral human fetal striatal transplantation in Huntington's disease. Neurology (2002) 58:1704.
   PubMedGoogle Scholar
• ROSSER AE, BARKER RA, HARROWER T et al.: Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN No 36485475. J. Neurol Neurosurg. Psychiatry (2002) 73:678–685.
   PubMed Web of Science ®Google Scholar
• BENSADOUN JC, DE ALMEIDA LP, DREANO M, AEBISCHERP, DEGLON N: Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. Eur. Neurosci. (2001) 14:1753–1761.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-SERRANO A, BJORKLUND A: Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. Neurosci.(1996) 16:4604–4616.
   Google Scholar
• PEREZ-NAVARRO E, ALBERCH J, ARENAS E, CALVO N, MARSALJ: Nerve growth factor and basic fibroblast growth factor protect cholinergic neurons against quinolinic acid excitotoxicity in rat neostriatum. Eur Neurosci. (1994) 6:706–711.
   PubMedGoogle Scholar
• ZEEVALK GD, MANZINO L, SONSALLA PK: Protection of malonate-induced GABA but not dopamine loss by GABA transporter blockade in rat striatum. Exp. Neurol (2002) 176:193–202.
   PubMedGoogle Scholar
• VARANI K, RIGAMONTI D, SIPIONE S et al: Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin. FASEB (2001) 15:1245–1247.
   PubMed Web of Science ®Google Scholar